

Resource Summary Report

Generated by [dkNET](#) on Jul 28, 2026

PE anti-human CD19

RRID:AB_2750097

Type: Antibody

Proper Citation

BioLegend Cat# 392506, RRID:AB_2750097

Antibody Information

URL: http://antibodyregistry.org/AB_2750097

Proper Citation: BioLegend Cat# 392506, RRID:AB_2750097

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone 4G7

Antibody ID: AB_2750097

Vendor: BioLegend

Catalog Number: 392506

Alternative Catalog Numbers: 392505

Record Creation Time: 20250820T053937+0000

Record Last Update: 20250820T220820+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human CD19.

No alerts have been found for PE anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. *Cell*, 188(9), 2372.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. *Journal of medical virology*, 96(5), e29630.

Zheng Z, et al. (2022) Uncovering the emergence of HSCs in the human fetal bone marrow by single-cell RNA-seq analysis. *Cell stem cell*, 29(11), 1562.

Rodríguez A, et al. (2021) MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. *Cell stem cell*, 28(1), 33.

Lu Y, et al. (2020) Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity. *Cell*, 180(6), 1081.

Lu Y, et al. (2020) Protocol for Single-Cell Analysis of Tumor-Infiltrating B Cells Isolated from Human Breast Cancer Tissue Before and After Neo-adjuvant Chemotherapy. *STAR protocols*, 1(1), 100040.